Schrödinger, Inc. (NASDAQ:SDGR – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $32.11.
SDGR has been the subject of a number of analyst reports. KeyCorp boosted their price objective on shares of Schrödinger from $25.00 to $27.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. BMO Capital Markets boosted their target price on shares of Schrödinger from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th.
Get Our Latest Research Report on Schrödinger
Institutional Investors Weigh In On Schrödinger
Schrödinger Trading Down 0.8 %
SDGR stock opened at $25.67 on Wednesday. The firm has a market cap of $1.87 billion, a PE ratio of -10.97 and a beta of 1.61. Schrödinger has a 1 year low of $16.67 and a 1 year high of $33.63. The company has a fifty day simple moving average of $21.60 and a 200 day simple moving average of $20.27.
Schrödinger (NASDAQ:SDGR – Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12). Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The company had revenue of $35.30 million for the quarter, compared to analyst estimates of $41.25 million. During the same period in the prior year, the company posted ($0.86) EPS. The business’s revenue was down 17.1% on a year-over-year basis. As a group, analysts forecast that Schrödinger will post -2.37 EPS for the current fiscal year.
About Schrödinger
Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.
See Also
- Five stocks we like better than Schrödinger
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Volatility ETFs to Help You Profit from Market Chaos
- How to Evaluate a Stock Before Buying
- Lam Research: Is a NAND Upgrade Cycle the Next Growth Catalyst?
- How to Effectively Use the MarketBeat Ratings Screener
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
Receive News & Ratings for Schrödinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrödinger and related companies with MarketBeat.com's FREE daily email newsletter.